Equillium EQ 深 沪
已收盘 08-21 16:00:00 美东时间
2.31
+0.040
+1.76%
华盛通- 最 高2.4641
- 今 开2.30
- 成交量 55.74万股
- 最 低 2.24
- 昨 收 2.27
- 总市值 1.46亿
- 52周最高 3.54
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 0.7562
- 委 比 -67.78%
- 总股本 6340.81万
- 历史最高 27.05
- 量 比 1.39
- 振 幅 9.87%
- 历史最低 0.27
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-15 02:40
Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-14 10:30
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $20.
07-13 17:38
Equillium Shareholders Approve Reverse Split and Capital Changes
Equillium ( ($EQ) ) has shared an announcement. On May 28, 2026, Equillium, Inc...
05-30 04:51
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.
05-29 01:32
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Equillium, a biotech company, will host a virtual investor event on May 27 at 11:00 AM ET, featuring Stephen Connelly Ph.D., discussing new preclinical data on AhR modulators and the relationship between AhR activation and miR-124 induction. The webinar will explore a unifying mechanism linking AhR signaling to miR-124, with implications for inflammatory disease therapies. EQ504, an investigational AhR modulator, is highlighted for its potential ...
05-20 20:05
Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 75 percent increase over losses of $(0.24) per share from the same
05-14 04:54
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Equillium reported Q1 2026 financial results with $61.3M in cash and plans to initiate a Phase 1 study for EQ504 in mid-2026. Snehal Naik, Ph.D., was appointed Chief Development Officer, bringing extensive experience in immunology and clinical development. EQ504, a potent AhR modulator, showed promising preclinical data supporting its potential for treating ulcerative colitis and other inflammatory diseases. The company also highlighted progress ...
05-13 20:01
